Antitrust IntelligenceAntitrust IntelligenceAntitrust Intelligence
Sign in
Notification
Font ResizerAa
  • For Lawyers
    For Lawyers
    Here, you’ll find the regulatory trends and hidden market shifts that others miss. You’ll learn where markets (and your clients’ industries) are heading—and how to…
    Show More
    Latest News
    Apple, Meta Refusal to Comply with EU rules May Bring New Fines, But Profits Too
    July 20, 2025
    Getty Images + Shutterstock: A Deal That Puts UK Regulator to the Test
    July 16, 2025
    Meta Bets Big on Smart Glasses, But Money is on Ads, Not Hardware
    July 15, 2025
    OpenAI–Google AI Browser War Exposes Limits of EU Tech Rules
    July 14, 2025
  • For Investors
    For Investors
    Regulatory events move markets—often faster than earnings reports. A merger approval or a hefty fine can send a stock soaring or sinking in a day.…
    Show More
    Latest News
    New EU rules targeting Shein and Temu Likely to Benefit Zalando
    July 18, 2025
    Symrise: How to benefit from a Cartel Investigation
    July 16, 2025
    Bank Pekao: On Its Way to lead Poland’s financial sector
    July 14, 2025
    Nexi: Solid Numbers With Regulatory Events as Catalysts
    July 14, 2025
  • News
    News
    Stay informed with our global antitrust news compilation—bringing you the latest developments, regulatory updates, and key cases from around the world, all in one place
    Show More
    Latest News
    EU Launches Legal Action Against Spain Over Bank Merger Rules
    July 21, 2025
    Zuckerberg, Meta Executives Settle $8 Billion Privacy Lawsuit
    July 18, 2025
    Turkish Authority Opens Antitrust Probe into Mastercard and Visa
    July 18, 2025
    Malaysia Fines Three Contractors for Bid Rigging
    July 17, 2025
  • Why Join?
  • Memberships
Reading: Bristol’s $74 Billion Celgene M&A Likely Gains Quick EU Approval
Font ResizerAa
Antitrust IntelligenceAntitrust Intelligence
Search
  • For Lawyers
  • For Investors
  • News
  • Why Join?
  • Memberships
Have an existing account? Sign In
Follow US
Lawyers

Bristol’s $74 Billion Celgene M&A Likely Gains Quick EU Approval

Editorial
Last updated: March 10, 2025 9:46 am
Editorial
Published February 22, 2019
Share

Rationale of the deal

The transaction will likely be approved as the companies’ portfolios are mostly complementary, though an overlap between Opdivo and Celgene/BeiGene’s pipeline PD-1 drug tislelizumab may raise concerns. The latter is expected to be returned to BeiGene. EU regulators have defined the market for pharmaceutical products very narrowly, so broad overlaps in immunology won’t raise concerns. Yet the EU’s increasing attention to future competition between pipeline products or even research projects suggest that other divestitures can’t be completely ruled out.

Contents
Rationale of the dealMinor divestitures needed, if at all.Approvals likely in 2H

Minor divestitures needed, if at all.

Additionally, the companies may have a problem with the expected synergies from the deal. While savings and cuts are welcome by shareholders, regulators may have a different view. R&D cuts in pharma deals are usually seen negatively by EU regulators because they could curtail innovation, make fewer drugs available to consumers and at higher prices. EU regulators will analyze whether the estimated $875 million R&D cuts from overlapping resources and early-stage portfolio is an attempt to scrap research that could lead to new, potentially competing drugs just to reinforce a monopoly position. If regulators consider these cuts to be anticompetitive, the companies may be asked to sell these research assets to competitors that could develop the drugs.

Source: Bristol Company Presentation

Approvals likely in 2H

Bristol-Celgene is expected to get an antitrust approval first from the US Federal Trade Commission, after the parties refiled the deal on February 20. The US regulator could nod the deal in 2Q. The European Commission, the EU’s antitrust regulator, will likely approve the deal in 2Q or just before its summer break after a 25-working-day phase one review. If remedies are needed, this deadline will likely be extended 10 more working days. The parties haven’t filed yet the deal in Brussels, but they are still on track to get the approval in time for the expected 3Q closing. Bristol-Myers has likely engaged in pre-notification talks with EU regulators to clear the way for a speedy approval.

You Might Also Like

OECD List with Most and Least Competitive Industries

Bertelsmann Chief Eyes Revival of $4.15 Billion TF1-M6 Merger Amid Regulatory Shifts

FIS-Worldpay $34 Billion Deal Nears Closing as FTC Grants Approval

Brussels Pressures Italy to Lift Golden Power Hurdles on UniCredit Deal

Mexico’s Supreme Court Boosts Regulator’s Power to Collect Confidential Information

TAGGED:bristolmerger

Weekly Newsletter

Insights you can turn into money or clients
Investors

Symrise: How to benefit from a Cartel Investigation

Editorial
Editorial
July 16, 2025
New EU rules targeting Shein and Temu Likely to Benefit Zalando
Antitrust Intelligence

About Us

We identify and quantify regulatory risks so you can take better decisions
Menu
  • Lawyers
  • Investors
  • News
  • My Bookmarks
  • About Us
  • Contact
Legals
  • Cookie Policy
  • Terms & Conditions
  • Privacy Policy

Subscribe Us

Subscribe to our newsletter to get weekly ideas to make money and get new clients!

© 2025 Antitrust Intelligence. All Rights Reserved. - Web design Málaga by Seb creativos
Antitrust Intelligence
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}
Antitrust & Financial Markets? Download Your Free Guide NOW
Five tips to find unique regulatory intelligence
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?